ST 1891
Alternative Names: ST-1891Latest Information Update: 03 Sep 2024
At a glance
- Originator Sention
- Class
- Mechanism of Action Hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypothyroidism
Most Recent Events
- 04 Oct 2023 Sention Therapeutics completes a phase II trial in Hypothyroidism in USA (PO) (NCT05412979)
- 13 Jun 2022 Phase-II clinical trials in Hypothyroidism in USA (PO) (NCT05412979)